Andrea Flynn | Vice President & Head-Investor Relations |
Bruce Cozadd | Chairman & Chief Executive Officer |
Dan Swisher | President |
Rob Iannone | Executive Vice President, Global Head of R&D |
Renée Galá | Executive Vice President & Chief Financial Officer |
Kim Sablich | Executive Vice President & General Manager, North America |
Jessica Fye | JPMorgan |
Marc Goodman | SVB Leerink |
Ken Cacciatore | Cowen |
Jason Gerberry | Bank of America |
Brandon Folkes | Cantor |
David Amsellem | Piper Sandler |
Jeff Hung | Morgan Stanley |
Gary Nachman | BMO |
Madhu Kumar | Goldman Sachs |
Ami Fadia | Needham |
Gregory Renza | RBC |
Ashwani Verma | UBS |
Ladies and gentlemen, and thank you for standing by. Welcome to the Second Quarter 2022 Jazz Pharmaceuticals Earnings Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] I would now like to turn the call over to your host Andrea Flynn, Vice President and Head-Investor Relations.